Behind the scenes at Isomorphic Labs
We’re joined by Isomorphic Labs’ Chief Scientific Officer Miles Congreve and Chief AI Officer Max Jaderberg for an in-depth conversation. What’s next after Isomorphic’s $600 million raise this past winter — and are they finally ready to enter the clinic?
AI’s next moonshots
Over the past few years, AI models have made breakthroughs in biology, like when AlphaFold cracked protein structure, or RFdiffusion took a major step forward on de novo protein design. What big swings could come next? We’ll talk to pioneers on the bleeding edge about building autonomous labs, virtual cells, AI scientists, and more.
How the world's largest drugmakers are betting on AI’s future
AI experts are full of big ideas for new tech and new tools, but it takes investment to make those ideas a reality. We'll sit down with leaders of some of the world's largest drugmakers who are deciding which ideas move from the notebook to the real world, and which aren't ready for primetime. Hear how the biopharma industry's largest companies are betting on AI in 2025 and beyond.
Experts panel
Stay tuned — more to come.
AI in biopharma: New York City happy hour
How AI can tackle cancer — with Siddhartha Mukherjee
Earlier this year, Pulitzer-winning physician-author Siddhartha Mukherjee joined forces with LinkedIn co-founder Reid Hoffman to launch Manas AI. How does his long and varied career across researching, writing, and building biotechs shape his thinking on AI's role in medicine and drug discovery? Hear from one of science's most influential and prolific voices on the current powers and future potential of this new technology.
The ethics of AI in science and healthcare
Silicon Valley is about moving fast, while the world of medicine starts with first, doing no harm. How does that tension play out with AI's growing role in everything from lab research to clinical trials to medical care? We'll talk through the biggest ethical questions for the field, strategies to build responsible AI, and whether the societal challenges will ultimately be bigger than the technological.
In conversation with David Reese
Amgen Chief Techonology Officer David Reese sits down with Andrew Dunn to talk AI at Amgen.
